Earlier this month, at the American Society of Clinical Oncology annual meeting in Chicago, Onconova presented interim data from its Phase II ONTARGET study testing oral rigosertib as a single agent in transfusion-dependent, lower risk MDS patients...BofA Merrill Lynch and Citigroup are acting as joint book-running managers, BMO Capital Markets is acting as lead manager and Needham & Co., Wedbush Pacgrow Life Sciences and Janney Montgomery Scott are acting as co-managers for the proposed offering

The compound is currently undergoing early stage clinical trials for the treatment of leukemia and solid tumor cancer, with rights to all oncology applications licensed to its partner, Eisai Co...And although full terms of the Series C funding round were not disclosed, they did include the hitting of milestones on the fibrosis clinical trial, according to PRISM Pharma CFO, Dai Takehara...The offering is expected to close on June 17.

Autifony Therapeutics Ltd., of London, said Pfizer Venture Investments, the venture capital arm of Pfizer Inc., of New York, invested £5 million (US$7.7 million) to join existing investors SV Life Sciences, Imperial Innovations plc and UCL Business plc in its Series A financing round...The financing is expected to fund the lead program to clinical proof of concept for at least one hearing disorder indication. (See BioWorld Today, Aug. 23, 2011

Prosensa, based in Leiden, the Netherlands, has methodically moved two exon-skipping antisense oligonucleotide drugs into clinical development in Duchenne's muscular dystrophy (DMD) and has three preclinical assets lined up behind them...J.P. Morgan and Citigroup are acting as joint book-running managers for the offering, with Leerink Swann acting as lead manager and Wedbush PacGrow Life Sciences and KBC Securities acting as co-managers...Since we're not going to have clinical data at the time we

acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager...On Friday, the Vetex's shares (NASDAQ:VRTX) gained $1.60, closing at $79.49.

Underwriters for the proposed offering include JP Morgan, Cowen and Co., BofA Merrill Lynch, Canaccord Genuity and Wedbush PacGrow Life Sciences...Proceeds would be used to fund clinical trials, R&D for additional alpha-1 antitrypsin (AAT) indications, expanding distribution capabilities for additional territories

Proceeds will be used to fund ongoing and new clinical trials and development and commercialization efforts for pimavanserin, as well as activities for other product candidates and for general corporate purposes...Those personalized and targeted immunotherapies are aimed at providing significant and durable clinical benefit regardless of tumor origin, disease stage and prior treatments. (See BioWorld Today, Oct. 17, 2012...Receptos will use the proceeds to support clinical work in multiple sclerosis

The trial, which will enroll 300 patients, is based on results from a Phase IIb study in newly diagnosed AML patients, 60-75, presented at the American Society of Clinical Oncology conference in 2011...and Canada in partnership with the Leukemia and Lymphoma Society, which has previously supported the development of CPX-351 . (See BioWorld Today, Dec. 27, 2012.) The transaction, led by New York and San Diego-based life sciences venture capital firm Valence Life Sciences LLC, sold a total of 10,430

RepliCel Life Sciences Inc., of Vancouver, British Columbia, said it started clinical development of an autologous cell therapy for the treatment of a variety of chronic tendon injuries, including Achilles, patellar and elbow

LLC and Wedbush PacGrow Life Sciences...Scioderm is advancing SD-101, a topical cream with a unique mechanism of action, into clinical development in epidermolysis bullosa (EB), a rare genetic condition that results in extremely fragile skin that blisters and tears easily...In an open-label Phase II study conducted in children with simplex, recessive dystrophic EB or junctional EB, SD-101 application resulted in complete closure of 88 percent of target chronic lesions within one month. #kicker123

The financing, which brings the company's total raise to €46.2 million across three equity rounds, was led by new investor Saffelberg Investments with participation from the company's founders and current investors GIMV, Biotech Fund Flanders, Baekeland Fund, BioVest CVA, Life Sciences Partners, Aescap Venture and Ventech...AG014 comprises oral delivery of an anti-TNF antibody with proven clinical efficacy in IBD, resulting in local efficacy and an improved safety profile over systemic drugs...Shares

Coronado plans to use the proceeds to fund R&D, clinical trials and manufacture of supply as well as other corporate purposes...RepliCel Life Sciences Inc., of Vancouver, British Columbia, closed a private placement of 1.6 million units at C31 cents (US31 cents), raising C$509,502

Credit Suisse, Leerink Swann, Wedbush PacGrow Life Sciences and BMO Capital Markets are serving as underwriters for the proposed IPO...Funds will be used to progress the clinical development program for lead candidate, Pracinostat, its oral histone deacetylase inhibitor for advanced hematologic malignancies, and for other general corporate purposes

Array BioPharma Inc., of Boulder, Colo., reported clinical data at the International Myeloma Workshop in Kyoto, Japan, showing that ARRY-520, a selective KSP inhibitor, demonstrated single-agent activity in heavily pretreated patients with relapsed or refractory multiple myeloma, with 19 months median overall survival and a 16 percent overall response rate...VG Life Sciences Inc., of San Marino, Calif., disclosed positive results from stage 2 of its pre-investigational new drug application Phase I

VG Life Sciences Inc., of San Marino, Calif., said it signed a two-year commitment to provide funding toward the operational needs of the firm from current investor MedBridge LLC...During that period, MedBridge also will provide full administrative support for the company, allowing it to focus on clinical development of the therapeutic pipeline

NCIC Clinical Trials Group at Queen's University in Kingston, Ontario, is conducting four studies in various tumor types, which will "go a long way to helping us figure out" where to put the most resources, Look said...The multitude of clinical trials adds up to a program that "sounds like a heck of a burn requirement...and Wedbush PacGrow Life Sciences are acting as joint book-running managers for Oncolytics' offering in the U.S., and Paradigm Capital Inc

The life sciences venture firm viewed the drug as a turning point in treating patients with advanced metastatic cancer and providing them with "durable responses" – years of additional life, rather than weeks or months...The transaction is expected to close on Feb. 19.

That helps a little bit," Jonathon Kellerman, a partner in PwC's pharmaceutical and life sciences practice, told BioWorld Today...Intended as a conversation starter, the other draft guidance addresses the clinical development of drugs to treat early stages of Alzheimer's disease before the onset of overt dementia...The comment deadline for the guidance is April 9.

The company plans to use the funds to advance the clinical development programs for rindopepimut, an immunotherapy targeting epidermal growth factor variant III (EGFRvIII) that is in a registration trial in front-line glioblastoma multiforme (GBM), and CDX-011 (glembatamumab vedotin), a fully human monoclonal antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) that completed a Phase IIb study in breast cancer...The company will receive proceeds of $8 million, which it expects to use to